Premium
Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients
Author(s) -
Koiwa Fumihiko,
Kazama Junichiro J,
Tokumoto Akihide,
Onoda Noritaka,
Kato Hitoshi,
Okada Tomoyuki,
NiiKono Tomoko,
Fukagawa Masafumi,
Shigematsu Takashi
Publication year - 2005
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2005.00293.x
Subject(s) - sevelamer , medicine , fibroblast growth factor 23 , bicarbonate , endocrinology , calcium , phosphate , basic fibroblast growth factor , dialysis , gastroenterology , growth factor , parathyroid hormone , biochemistry , hyperphosphatemia , chemistry , receptor
Fibroblast growth factor 23 (FGF23) is a member of the fibroblast growth factor superfamily which displays a strong phosphaturic action and an inhibition of vitamin D 1‐α hydroxylase activity. Fourty‐six patients undergoing maintenance hemodialysis therapy participated in the study. They were randomly divided into 2 groups, and treated with either 3 g sevelamer hydrochloride + 3 g of calcium bicarbonate (CaCO 3 ), or 3 g of CaCO 3 alone. Serum FGF23 levels were determined by a sandwich enzyme‐linked immunosorbent assay (ELISA) system that detects the intact form of FGF23 molecules. Although the serum inorganic phosphate (Pi) levels were comparable before treatment, the levels were significantly lower in the patients treated with sevelamer hydrochloride + CaCO 3 than those with CaCO 3 alone after 4 weeks of treatment ( P < 0.05). Serum FGF23 levels significantly decreased after 4 weeks of the treatment with sevelamer hydrochloride + CaCO 3 from the pretreatment levels ( P < 0.05), while no changes were found in the patients treated with CaCO 3 alone. Thus, the use of sevelamer hydrochloride and CaCO 3 reduced serum FGF23 levels in dialysis patients presumably through inhibiting phosphate load into the intestine.